

Table S1. Reports of granulomatous and sarcoid-like lesions in the context of immune checkpoint inhibitors in patients with melanoma.

| Author | Number of cases | Type of events | ICI | Total number of patients treated | Incidence (%) (95% C.I) | Reference |
|--|-----------------|---|-----------------|----------------------------------|-------------------------|-----------|
| (Dimitriou, Frauchiger et al. 2018) | 1 | Mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | [35] |
| | 1 | Cutaneous | PD-1 | N/A | N/A | |
| | 2 | Cutaneous, mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | |
| (Tetzlaff, Nelson et al. 2018) | 1 | Cutaneous, mediastinal/ hilar lymphadenopathy | CTLA-4 | N/A | N/A | [30] |
| | 1 | Cutaneous, mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | |
| | 1 | Mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | |
| (Le Burel, Champiat et al. 2017) | 1 | Ocular, Cutaneous, pulmonary, lymphadenopathy | PD-1 | N/A | N/A | [36] |
| (Lomax, McGuire et al. 2017) | 1 | Pulmonary, cutaneous, lymphadenopathy | PD-1 | N/A | N/A | [28] |
| | 1 | Cutaneous, lymphadenopathy | PD-1 | N/A | N/A | |
| | 1 | Pulmonary | PD-1 | N/A | N/A | |
| (Reddy, Possick et al. 2017) | 2 | Cutaneous, pulmonary | CTLA-4 and PD-1 | N/A | N/A | [37] |
| (Toumeh, Sakhi et al. 2016) | 1 | Diffuse Lymphadenopathy | CTLA-4 | N/A | N/A | [38] |
| (Yatim, Mateus et al. 2018) | 1 | Cutaneous, pulmonary | PD-1 | N/A | N/A | [39] |
| (Firwana, Ravilla et al. 2017) | 1 | Cutaneous, mediastinal/ hilar lymphadenopathy | CTLA-4 | N/A | N/A | [40] |
| | 1 | Diffuse lymphadenopathy, spleen | CTLA-4 | N/A | N/A | |
| | 1 | Cutaneous, pulmonary, diffuse lymphadenopathy | PD-1 | N/A | N/A | |
| (Danlos, Pages et al. 2016) | 1 | Cutaneous, mediastinal lymphadenopathy | PD-1 | N/A | N/A | [17] |
| (Martinez Leborans, Esteve Martinez et al. 2016) | 1 | Cutaneous | CTLA-4 | N/A | N/A | [41] |
| (Tissot, Carsin et al. 2013) | 1 | Cutaneous, pulmonary, mediastinal lymphadenopathy | CTLA-4 | N/A | N/A | [42] |
| (Eckert, Schoeffler et al. 2009) | 1 | Cutaneous, pulmonary, mediastinal lymphadenopathy | CTLA-4 | N/A | N/A | [43] |

| | | | | | | |
|--|---|---|--------|-----|------------------------|------|
| (Seve, Schott et al. 2009) | 1 | pulmonary | CTLA-4 | N/A | N/A | [44] |
| (Reule and North 2013) | 1 | Cutaneous, pulmonary | CTLA-4 | N/A | N/A | [45] |
| (McKenna, Molloy et al. 2018) | 1 | Cutaneous, pulmonary, diffuse lymphadenopathy | PD-1 | N/A | N/A | [46] |
| (Jespersen, Bjursten et al. 2018) | 1 | Cutaneous, mediastinal lymphadenopathy | PD-1 | N/A | N/A | [47] |
| (Burillo-Martinez, Morales-Raya et al. 2017) | 1 | Cutaneous, pulmonary | PD-1 | N/A | N/A | [48] |
| | 1 | Cutaneous (Granuloma-tous panniculitis) | PD-1 | N/A | N/A | |
| (Andersen, Nor-gaard et al. 2014) | 1 | Spleen | CTLA-4 | N/A | N/A | [26] |
| (Balestra, Ben-zaquen et al. 2017) | 1 | Pulmonary, mediastinal lymphadenopathy | PD-1 | N/A | N/A | [49] |
| (Cheshire, Board et al. 2018) check | 2 | Mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | [50] |
| | 1 | Cutaneous, mediastinal/ hilar lymphadenopathy | PD-1 | N/A | N/A | |
| (Wesselius, DeLeon et al. 2018) | 1 | Lymphadenopathy | PD-1 | N/A | N/A | [51] |
| (Gutzmer, Koop et al. 2017) | 1 | Pulmonary | PD-1 | N/A | N/A | [52] |
| (Lidar, Giat et al. 2018) | 2 | Pulmonary | PD-1 | 12 | 16.66 (4.70- 44.80) | [53] |
| (Al-Dliw, Megri et al. 2017) | 1 | Pulmonary | PD-1 | N/A | N/A | [54] |
| (Nandavaram and Nadkarni 2018) | 1 | Mediastinal/ hilar lymphadenopathy | CTLA-4 | N/A | N/A | [55] |
| (Wilgenhof, Morlion et al. 2012) | 1 | Pulmonary, diffuse lymphadenopathy, spleen | CTLA-4 | N/A | N/A | [56] |
| (Murphy, Kennedy et al. 2014) | 1 | Mediastinal/ hilar lymphadenopathy, CNS | CTLA-4 | N/A | N/A | [57] |
| (Berthod, Lazor et al. 2012) | 1 | Pulmonary | CTLA-4 | N/A | N/A | [58] |
| (Vogel, Guislain et al. 2012) | 1 | Mediastinal/ hilar lymphadenopathy | CTLA-4 | N/A | N/A | [59] |
| (Montaudie, Pradelli et al. 2017) | 1 | Pulmonary, Parotid gland | PD-1 | N/A | N/A | [60] |
| (Koelzer, Rothschild et al. 2016) | 1 | Pulmonary | PD-1 | N/A | N/A | [61] |
| (Bronstein, Ng et al. 2011) | 8 | Pulmonary, diffuse lymphadenopathy | CTLA-4 | 119 | 6.72 (3.45- 12.71) | [62] |
| (Gilardi, Colandrea et al. 2014) | 1 | Mediastinal, hilar lymphadenopathy, rectus abdominus muscle | CTLA-4 | N/A | N/A | [63] |
| (Arellano, Mosley et al. 2018) | 1 | Diffuse lymphadenopathy | CTLA-4 | N/A | N/A | [64] |
| (Brahmer, Tykodi et al. 2012) | 1 | Sarcoidosis (not otherwise specified) | PD-1 | N/A | N/A | [65] |
| (Jiang, Patino et al. 2018) | 1 | Cutaneous | PD-1 | N/A | N/A | [66] |

| | | | | | | |
|---|---|---|-----------------|-----|---------------------|------|
| (Tetzlaff, Jazaeri et al. 2017) | 2 | Cutaneous | CTLA 4 and PD-1 | N/A | N/A | [67] |
| (Wu, Kwong et al. 2018) | 3 | Cutaneous | PD-1 | N/A | N/A | [68] |
| (Kubicki, Welborn et al. 2018) | 3 | Cutaneous | CTLA-4 | N/A | N/A | [69] |
| (Perret, Josselin et al. 2017) | 2 | Cutaneous | CTLA-4 | N/A | N/A | [70] |
| (Diaz-Perez, Beveridge et al. 2018) | 1 | Cutaneous | CTLA-4 | N/A | N/A | [71] |
| (Chorti, Kanaki et al. 2020) | 8 | Mediastinal/hilar lymphadenopathy | PD-1 and CTLA-4 | 45 | 17.78 (9.29- 31.33) | [72] |
| | 1 | Cutaneous, pulmonary | PD-1 and CTLA-4 | 45 | 2.22 (0.39- 11.57) | |
| | 1 | Cutaneous | PD-1 and CTLA-4 | 45 | 2.22 (0.39- 11.57) | |
| (Mobini, Dhillon et al. 2019) | 2 | Cutaneous | PD-1, CTLA-4 | N/A | N/A | [73] |
| (Reuss, Kunk et al. 2016) | 1 | Hilar, subcarinal lymphadenopathy, cutaneous | PD-1 and CTLA-4 | N/A | N/A | [74] |
| (Rodriguez, Lipson et al. 2019) | 3 | Mediastinal/hilar lymphadenopathy | PD-1 | N/A | N/A | [75] |
| | 1 | Mediastinal/ hilar lymphadenopathy | CTLA -4 | N/A | N/A | |
| | 1 | Mediastinal/ hilar lymphadenopathy | PD-1 and CTLA-4 | N/A | N/A | |
| Laroche (Laroche, Alarcon Chinchilla et al. 2018) | 1 | Cutaneous, Pulmonary | PD-1 | N/A | N/A | [76] |
| (Tan, Malinzak et al. 2018) | 1 | Neuro-sarcoidosis, mediastinal, hilar lymphadenopathy | PD-1 and CTLA-4 | N/A | N/A | [77] |
| (Dunn-Pirio, Shah et al. 2018) | 1 | Neuro-sarcoidosis | PD-1 and CTLA-4 | N/A | N/A | [78] |
| (Ung and Gragoudas 2020) | 1 | Mediastinal/hilar lymphadenopathy, lung, eye | PD-1 | N/A | N/A | [24] |
| (Tulbah, Rowe et al. 2019) | 1 | Mediastinal/hilar lymphadenopathy, bone | PD-1 | N/A | N/A | [79] |
| (Fukuchi, Hikawa et al. 2019) | 1 | Pulmonary, Mediastinal/hilar lymphadenopathy, eye | PD-1 | N/A | N/A | [80] |
| (Lise and Audrey 2017) | 1 | Mediastinal/hilar lymphadenopathy, lung, eye | PD-1 | N/A | N/A | [81] |
| (Nishino, Sholl et al. 2018) | 4 | lung | PD-1 | N/A | N/A | [82] |
| (Smith, Mitchell et al. 2018) | 1 | Mediastinal/hilar lymphadenopathy, lung, cutaneous | PD-1 | N/A | N/A | [83] |

| | | | | | | |
|--|---|---|-----------------|-----|-----|------|
| (Wang, Patel et al. 2018) | 1 | Cutaneous | PD-1 | N/A | N/A | [84] |
| (Woodbeck, Metelitsa et al. 2018) | 1 | Cutaneous | PD-1 | N/A | N/A | [85] |
| (Lu 2019) | 1 | Mediastinal/hilar lymphadenopathy, cutaneous | PD-1 | N/A | N/A | [86] |
| (Marcoval, Bauer-Alonso et al. 2021) | 1 | Cutaneous | PD-1 | N/A | N/A | [87] |
| (Garanzini, Scaramuzza et al. 2020) | 1 | Mediastinal/hilar lymphadenopathy, lung, spleen | CTLA-4 | N/A | N/A | [88] |
| (Cervantes, Rosen et al. 2019) | 1 | Cutaneous | CTLA-4 | N/A | N/A | [89] |
| (Apalla, Kemanetzi et al. 2021) | 1 | Cutaneous | PD-1 and CTLA-4 | N/A | N/A | [27] |
| (Yasin, Yadala et al. 2021) | 1 | Hilar/ mediastinal lymphadenopathy | CTLA-4 | N/A | N/A | [90] |
| Abbreviations: CTLA4; cytotoxic T-lymphocyte antigen 4, ICI; immune checkpoint inhibitor, PD1; programmed cell death 1 | | | | | | |

References

1. Dimitriou, F.; Frauchiger, A.L.; Urošević-Maiwald, M.; Naegeli, M.C.; Goldinger, S.M.; Barysch, M.; Franzen, D.; Kamarachev, J.; Braun, R.; Dummer, R.; Mangana, J.. Sar-coid-like reactions in patients receiving modern melanoma treatment. *Melanoma Res.* **2018**, *28*(3), 230–236.
2. Le Burel, S.; Champiat, S.; Mateus, C.; Marabelle, A.; Michot, J.M.; Robert, C.; Belkhir, R.; Soria, J.C.; Laghouati, S.; Voisin, A.L., et al. Prevalence of im-mune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. *Eur J Cancer.* **2017**, *82*, 34–44.
3. Reddy, S.B.; Possick, J.D.; Kluger, H.M.; Galan, A.; Han, D. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. *J. Immunother.* **2017**, *40*, 307–311, <https://doi.org/10.1097/cji.0000000000000181>.
4. Toumeh, A.; Sakhi, R.; Shah, S.; Arudra, S.K.; De Las Casas, L.E., Skeel, R.T. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma. *Am J Ther.* **2016**, *23*(4), e1068–1071.
5. Yatim, N.; Mateus, C.; Charles, P. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. **2018**, *39*, 130–133, <https://doi.org/10.1016/j.revmed.2017.11.008>.
6. Firwana, B.; Ravilla, R.; Raval, M.; Hutchins, L.; Mahmoud, F.. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. *J Oncol Pharm Pract.* **2017**, *23*(8), 620–624.
7. Martinez, L.L.; Esteve, M.A.; Victoria, M.A.M.; Alegre, d.M.V.; Berrocal, J.A. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. *Dermatol Ther.* **2016**, *29*(5), 306–308.
8. Tissot, C.; Carsin, A.; Freymond, N.; Pacheco, Y.; Devouassoux, G.; Naeije, R.; Chemla, D.; Dinh-Xuan, A.T.; Noordegraaf, A.V. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. *Eur. Respir. J.* **2012**, *41*, 246–247, <https://doi.org/10.1183/09031936.00107912>.
9. Eckert, A.; Schoeffler, A.; Dalle, S.; Phan, A.; Kiakouama, L.; Thomas, L.. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. *Dermatology.* **2009**, *218*(1), 69–70.
10. Seve, P.; Schott, A.M.; Pavic, M.; Broussolle, C.; Gilis, L.; Thomas, L. Sarcoidosis and Melanoma: A Referral Center Study of 1,199 Cases. *Dermatology* **2009**, *219*, 25–31, <https://doi.org/10.1159/000213245>.
11. Reule, R.B.; North, J.P. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. *J Am Acad Dermatol.* **2013**, *69*(5), e272–e273.
12. McKenna, M.C.; Molloy, K.; Crowther, S.; Feeney, J.; Gillis, A.; Connolly, M.; Kelleher, F. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars. *J. Oncol. Pr.* **2018**, *14*, 200–201, <https://doi.org/10.1200/jop.2017.027383>.
13. Jespersen, H.; Bjursten, S.; Ny, L.; Levin, M. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. *Lancet Oncol.* **2018**, *19*, e327, [https://doi.org/10.1016/s1470-2045\(18\)30252-3](https://doi.org/10.1016/s1470-2045(18)30252-3).
14. Burillo-Martinez, S.; Morales-Raya, C.; Prieto-Barrios, M.; Rodriguez-Peralto, J.L.; Ortiz-Romero, P.L.. Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum. *JAMA Dermatol.* **2017**, *153*(7), 721–722.
15. Balestra, R.; Benzaquen, S.; Wang, J. Sarcoidosis-like Granulomatous Lung Reaction Associated with Anti-Programmed Death Receptor-1 Ligand Therapy. *Ann. Am. Thorac. Soc.* **2017**, *14*, 296–299, <https://doi.org/10.1513/annalsats.201611-863le>.
16. Cheshire, S.C.; Board, R.E.; Lewis, A.R.; Gudur, L.D.; Dobson, M.J. .Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma. *Radiology.* **2018**, *289*(2), 564–567.
17. Wesselius, L.J.; DeLeon, T.T.; Gotway, M.B. A Sarcoidlike Reaction Mimicking Metastatic Malignancy in a Patient With Melanoma Treated With Pembrolizumab. *Am. J. Roentgenol.* **2018**, *210*, W183–W184, <https://doi.org/10.2214/ajr.17.19144>.
18. Gutzmer, R.; Koop, A.; Meier, F.; Hassel, J.C.; Terheyden, P.; Zimmer, L.. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. *Eur J Cancer.* **2017**, *75*, 24–32.
19. Lidar, M.; Giat, E.; Garelick, D.; Horowitz, Y.; Amital, H.; Steinberg-Silman, Y.. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. *Autoimmun Rev.* **2018**, *17*(3), 284–289.

20. Al-Dliw, M.; Megri, M.; Shahoub, I.; Sahay, G.; Limjoco, T.I.; Shweihat, Y.. Pembrolizumab reactivates pulmonary granulomatosis. *Respir Med Case Rep.* **2017**, *22*, 126–129. 55
21. Nandavaram, S.; Nadkarni, A. Ipilimumab-Induced Sarcoidosis and Thyroiditis. *Am. J. Ther.* **2018**, *25*, e379–e380, <https://doi.org/10.1097/mjt.0000000000000545>. 56
22. Wilgenhof, S.; Morlion, V.; Seghers, A.C.; Du Four, S.; Vanderlinden, E.; Hanon, S.. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. *Anticancer Res.* **2012**, *32*(4), 1355–1359. 57
23. Murphy, K.P.; Kennedy, M.P.; Barry, J.E.; O'Regan, K.N.; Power, D.G.. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. *Oncol Res Treat.* **2014**, *37*(6), 351–353. 58
24. Berthod, G.; Lazor, R.; Letovanec, I.; Romano, E.; Noirez, L.; Mazza-Stalder, J.; Speiser, D.; Peters, S.; Michel, O. Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab. *J. Clin. Oncol.* **2012**, *30*, e156–e159, <https://doi.org/10.1200/jco.2011.39.3298>. 59
25. Vogel, W.V.; Guislain, A.; Kvistborg, P.; Schumacher, T.N.; Haanen, J.B.; Blank, C.U.. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. *J Clin Oncol.* **2012**, *30*(2), e7–e10. 60
26. Montaudie, H.; Pradelli, J.; Passeron, T.; Lacour, J.P.; Leroy, S.. Pulmonary sarcoid-like granulomatosis induced by nivolumab. *Br J Dermatol.* **2017**, *176*(4), 1060–1063. 61
27. Koelzer, V.H.; Rothschild, S.I.; Zihler, D.; Wicki, A.; Willi, B.; Willi, N.. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. *J Immunother Cancer.* **2016**, *4*, 13. 62
28. Bronstein, Y.; Ng, C.S.; Hwu, P.; Hwu, W.-J. Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy. *Am. J. Roentgenol.* **2011**, *197*, W992–W1000, <https://doi.org/10.2214/ajr.10.6198>. 63
29. Gilardi, L.; Colandrea, M.; Vassallo, S.; Travaini, L.L.; Paganelli, G.. Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation. *Clin Nucl Med.* **2014**, *39*(5), 472–474. 64
30. Arellano, K.; Mosley, J.C.; Moore, D.C.. Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis. *J Pharm Pract.* **2018**, *31*(2), 227–229. 65
31. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med.* **2012**, *366*(26), 2455–2465. 66
32. Jiang, B.; Patino, M.M.; Gross, A.J.; Leong, S.P.L.; Moretto, J.C.; Kashani-Sabet, M.. Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy. *JAAD Case Rep.* **2018**, *4*(1), 13–16. 67
33. Tetzlaff, M.T.; Jazaeri, A.A.; Torres-Cabala, C.A.; Korivi, B.R.; Landon, G.A.; Nagarajan, P.; Choksi, A.; Chen, L.; Uemura, M.; Aung, P.P.; et al. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. *J. Cutan. Pathol.* **2017**, *44*, 1080–1086, <https://doi.org/10.1111/cup.13044>. 68
34. Wu, J.; Kwong, B.; Martires, K.; Rieger, K.; Hung, S.-I.; Iyer, G.; Lacouture, M. Granuloma annulare associated with immune checkpoint inhibitors. *J. Eur. Acad. Dermatol. Venereol.* **2017**, *32*, e124–e126, <https://doi.org/10.1111/jdv.14617>. 69
35. Kubicki, S.L.; Welborn, M.E.; Garg, N.; Aung, P.; Patel, A.B. Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis). *J. Cutan. Pathol.* **2018**, *45*, 636–638, <https://doi.org/10.1111/cup.13267>. 70
36. Perret, R.E.; Josselin, N.; Knol, A.-C.; Khammari, A.; Cassecuel, J.; Peuvrel, L.; Dreno, B.; Supported by GESTAMP Nantes group of cutaneous adverse events induced by anticancer drugs Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. *Int. J. Dermatol.* **2017**, *56*, 527–533, <https://doi.org/10.1111/ijd.13540>. 71
37. Diaz-Perez, J.A.; Beveridge, M.G.; Victor, T.A.; Cibull, T.L. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer. *J. Cutan. Pathol.* **2018**, *45*, 434–438, <https://doi.org/10.1111/cup.13133>. 72
38. Chorti, E.; Kanaki, T.; Zimmer, L.; Hadaschik, E.; Ugurel, S.; Gratsias, E.; Roesch, A.; Bonella, F.; Wessendorf, T.E.; Wälscher, J.; et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. *Eur. J. Cancer* **2020**, *131*, 18–26, <https://doi.org/10.1016/j.ejca.2020.02.024>. 73
39. Mobini, N.; Dhillon, R.; Dickey, J.; Spoon, J.; Sadrolashrafi, K. Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with 74

- Unusual Manifestations and Review of the Literature.. *Case Rep. Dermatol. Med.* **2019**, 2019, 6702870–7, <https://doi.org/10.1155/2019/6702870>. 108
40. Reuss, J.E.; Kunk, P.R.; Stowman, A.M.; Gru, A.A.; Slingluff, C.L.; Gaughan, E.M. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. *J. Immunother. Cancer* **2016**, 4, 94, <https://doi.org/10.1186/s40425-016-0199-9>. 109
41. Rodriguez, E.F.; Lipson, E.; Suresh, K.; Cappelli, L.C.; Monaco, S.E.; Maleki, Z.. Immune checkpoint block-er-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspi-ration cytology of patients treated for advanced malignant melanoma. *Hum Pathol.* **2019**, 91, 69–76. 110
42. Laroche, A.; Alarcon, C.E.; Bourgeault, E.; Dore, M.A.. Erythema Nodosum as the Initial Presen-tation of Nivolumab-Induced Sarcoidosis-Like Reaction. *J Cutan Med Surg.* **2018**, 22(6), 627–629. 111
43. Tan, I.; Malinzak, M.; Salama, A.K.S.. Delayed onset of neurosarcoidosis after concurrent ipili-mumab/nivolumab therapy. *J Immunother Cancer.* **2018**, 6(1), 77. 112
44. Dunn-Pirio, A.M.; Shah, S.; Eckstein, C. Neurosarcoidosis following Immune Checkpoint Inhibition. *Case Rep. Oncol.* **2018**, 11, 521–526, <https://doi.org/10.1159/000491599>. 113
45. Tulpah, R.I.; Rowe, S.P.; Solnes, L.B.; Javadi, M.S. Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary. *Clin. Nucl. Med.* **2019**, 44, e519–e521, <https://doi.org/10.1097/rnu.0000000000002724>. 114
46. Fukuchi, K.; Hikawa, M.; Sano, Y.; Kasuya, A.; Aoshima, M.; Tatsuno, K.. Sarcoid-like reaction and viti-ligo occurring after nivolumab therapy in a patient with metastatic melanoma. *J Dermatol.* **2019**, 46(10), e359–e360. 115
47. Lise, Q.-K.; Audrey, A.-G. Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pem-brolizumab. *Am. J. Ophthalmol. Case Rep.* **2016**, 5, 92–93, <https://doi.org/10.1016/j.ajoc.2016.12.014>. 116
48. Nishino, M.; Sholl, L.M.; Awad, M.M.; Hatabu, H.; Armand, P.; Hodi, F.S.. Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Im-mune-Related Adverse Event. *Cancer Immunol Res.* **2018**, 6(6), 630–635. 117
49. Smith, R.J.; Mitchell, T.C.; Chu, E.Y. Pembrolizumab-induced sarcoidal infusion site reaction. *J. Cutan. Pathol.* **2018**, 45, 727–729, <https://doi.org/10.1111/cup.13307>. 118
50. Wang, L.; Patel, G.; Chiesa-Fuxench, Z.C.; Mcgettigan, S.; Schuchter, L.; Mitchell, T.C.; Ming, M.E.; Chu, E.Y. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibi-tor Therapy. *JAMA Dermatol.* **2018**, 154, 1057–1061, <https://doi.org/10.1001/jamadermatol.2018.1912>. 119
51. Woodbeck, R.; Metelitsa, A.I.; Naert, K.A.. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. *Am J Dermatopathol.* **2018**, 40(7), 523–526. 120
52. Lu, Y. FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis. *Clin. Nucl. Med.* **2019**, 44, 167–168, <https://doi.org/10.1097/rnu.0000000000002408>. 121
53. Marcoval, J.; Bauer-Alonso, A.; Fornons-Servent, R.; Jiménez-Colomo, L.; Sabaté-Llobera, A.; Penín, R. Subcu-taneous sarcoidosis induced by pembrolizumab in a melanoma patient mimicking subcutaneous metastasis at 18F-FDG PET/CT. **2020**, 40, 255–256, <https://doi.org/10.1016/j.remnie.2020.09.004>. 122
54. Garanzini, E.M.; Scaramuzza, D.; Spadarella, G.; Di Guardo, L.; Marchianò, A. Sarcoidosis-like disease mim-icking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. *BJR | case Rep.* **2020**, 6, <https://doi.org/10.1259/bjrcr.20190065>. 123
55. Cervantes, J.; Rosen, A.; Dehesa, L.; Dickinson, G.; Alonso-Llamazares, J.. Granulomatous Reaction in a Pa-tient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cuta-neous Findings. *Actas Dermosifiliogr (Engl Ed).* **2019**, 110(1), 43–49. 124
56. Yasin, H.; Yadala, V.; Khan, N.A.J.; Graffeo, V.; Denning, K.; Lebowicz, Y.. Immunotherapy-Induced Sar-coid-Like Reaction: A Shrewd Imitator. *J Investig Med High Impact Case Rep.* **2021**, 9, 23247096211009400. 125